7 completed, 3 unknown, 1 active not recruiting, 1 recruiting. 14 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 7, Unknown 3, Active not recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Venous Leg Ulcer: new trials by email Literature Review of Venous Leg Ulcer trials Research Report on Venous Leg Ulcer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of XSTEM-VLU in Patients With Difficult-to-heal Venous Leg Ulcers XSTEM-VLU, Vehicle - Venous Leg Ulcer | Phase 1 / Phase 2 | Completed | Xintela AB | 6 | 2022-10-26 | 2026-06-26 |
| A Study to Evaluate ENERGI-F703 GEL in Venous Leg Ulcer ENERGI-F703 GEL, ENERGI-F703 GEL matched vehicle - Venous Leg Ulcer | Phase 2 | Unknown | Energenesis Biomedical Co., Ltd. | 80 | 2022-07-26 | 2024-02-20 |
| MTX-001 for the Treatment of Non-Healing Venous Stasis Ulcers MTX-001 (human amniotic fluid) - Venous Stasis Ulcer, Venous Leg Ulcer | Phase 2 | Recruiting | Merakris Therapeutics | 80 | 2022-02-26 | 2026-08-26 |
| Clinical Trial Enzyme Application Targeting Venous Leg Ulcers Aurase Wound gel - Venous Leg Ulcer, Leg Injuries and Disorders | Phase 2 | Completed | SolasCure Limited | 43 | 2021-08-09 | 2023-02-15 |
| A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers EscharEx (EX-02 formulation) - Venous Leg Ulcer, Diabetic Foot Ulcer | Phase 2 | Completed | MediWound Ltd | 12 | 2021-04-21 | 2022-07-26 |
| Effect of rhGM-CSF on the Healing of Venous Leg Ulcers rhGM-CSF + hydrogel, Placebo hydrogel, Standard care - Venous Leg Ulcer | Phase 2 | Unknown | Reponex Pharmaceuticals A/S | 6 | 2021-03-11 | 2022-11-17 |
| A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers EscharEx (5% EX-02 formulation), Gel Vehicle, Non-surgical standard of care (NSSOC) - Venous Leg Ulcer | Phase 2 | Completed | MediWound Ltd | 120 | 2019-12-02 | 2022-11-14 |
| Subjects With Non-Healing Venous Leg Ulcers Treated With Standard Care Plus Cryopreserved Human Umbilical Cord (TTAX01) TTAX01, Profore Compression Therapy, Cadexomer Iodine dressing - Venous Leg Ulcer | Phase 2 | Completed | BioTissue Holdings, Inc | 31 | 2019-02-14 | 2020-09-03 |
| Dose-response Relationship Study of S42909 on Leg Ulcer Healing S42909 100 mg, S42909 200 mg, S42909 400 mg - Venous Leg Ulcer | Phase 2 | Completed | Ilkos Therapeutic Inc. | 121 | 2017-09-12 | 2020-10-08 |
| A Prospective Randomized, Double-Blind, Placebo-Controlled Trial Comparing VitroGro® ECM to Placebo in Patients With Venous Leg Ulcers VitroGro® ECM, Dulbecco's Phosphate Buffered Saline - Venous Leg Ulcer | Phase 2 / Phase 3 | Withdrawn | Tissue Therapies Ltd. | 2017-01-01 | 2017-05-30 | |
| Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers 0.1% TR 987, Placebo gel - Venous Leg Ulcer | Phase 2 | Active not recruiting | SerenaGroup, Inc. | 80 | 2016-11-01 | 2020-10-22 |
| Aspirin for Venous Ulcers: Randomised Trial (AVURT) Aspirin, Placebo (for Aspirin) - Venous Leg Ulcer | Phase 2 | Terminated | St George's, University of London | 26 | 2015-07-10 | 2017-06-27 |
| Trial of Compassionate Use of hp802-247 to Treat Venous Leg Ulcers in Subjects Who Have Failed Multiple Other Healing Technologies Weekly wound spray with components 1 and 2 of the compound HP802-247 - Venous Leg Ulcer | Phase 2 | Unknown | Atlantic Health System | 5 | 2011-03-01 | 2011-03-22 |
| Dose Finding Study of HP802-247 in Venous Leg Ulcers HP802-247, Placebo (Vehicle) - Venous Leg Ulcer, Venous Stasis Ulcers | Phase 2 | Completed | Healthpoint | 228 | 2009-02-01 | 2016-10-24 |
Varicose Ulcer (14) · Leg Ulcer (3) · Diabetic Foot (1) · Disease (1) · Leg Injuries (1) · Wounds and Injuries (1)
Cardiovascular Diseases (14) · Skin Diseases (14) · Skin Ulcer (14) · Skin and Connective Tissue Diseases (14) · Varicose Veins (14) · Vascular Diseases (14) · Leg Ulcer (11) · Diabetes Complications (1) · Diabetes Mellitus (1) · Diabetic Angiopathies (1) · Diabetic Neuropathies (1) · Endocrine System Diseases (1) · Foot Ulcer (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Aspirin (1) · Gels (1) · Hydrogels (1) · Standard of Care (1) · beta-Glucans (1) · molgramostim (1) · regramostim (1)
MediWound Ltd (2) · Atlantic Health System (1) · BioTissue Holdings, Inc (1) · Energenesis Biomedical Co., Ltd. (1) · Healthpoint (1) · Ilkos Therapeutic Inc. (1) · Merakris Therapeutics (1) · Reponex Pharmaceuticals A/S (1) · SerenaGroup, Inc. (1) · SolasCure Limited (1) · St George's, University of London (1) · Tissue Therapies Ltd. (1) · Xintela AB (1)
United States (9) · Canada (2) · Hungary (2) · United Kingdom (2) · Argentina (1) · Austria (1) · Brazil (1) · Czechia (1) · Denmark (1) · Italy (1) · Poland (1) · Slovakia (1) · Spain (1) · Sweden (1) · Switzerland (1)
Eberhard Rabe, Professor (1) · Ewa A Burian, MD (1) · Herbert B Slade, MD (1) · Lior Rosenberg, Prof. (1) · Robert J Hinchliffe, MD, FRCS (1) · Robert J Snyder, MD (1) · Robert Kirsner, MD (1) · Scheffer Tseng, MD, PhD (1) · Thomas Serena, MD (1) · William Marston, MD (1)
PMID 22863328, PMID 26554558, PMID 30325305, PMID 31349862, PMID 39763591